5–fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5–fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer

Massimo Lopez, Paola Papaldo, Luigi Di Lauro, Patrizia Vici, Silvia Carpano, Ettore M S Conti

Research output: Contribution to journalArticlepeer-review

Abstract

94 evaluable patients with metastatic breast cancer were randomly assigned to 5-fiuorouracil, adriamycin, and cyclophosphamide (FAC) or 5-fluorouracil, epirubicin, and cyclophosphamide (FEC), with cycles repeated every 3 weeks. The objective response rate to FAC was 46% versus 44% to FEC. There was no significant difference in the median duration of response and median survival for the two regimens. Toxicity was more frequent and more pronounced in patients receiving FAC. Results indicate therapeutic equivalence of the two regimens and reduced toxicity of the epirubicin arm.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalOncology
Volume46
Issue number1
DOIs
Publication statusPublished - 1989

Keywords

  • Breast cancer
  • Chemotherapy
  • Epirubicin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of '5–fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5–fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer'. Together they form a unique fingerprint.

Cite this